News Overview

The company also reported reduced total expenses of ₹1,088.20 crore in Q4 FY25 against ₹1,094.4 crore in Q4 FY24, thus leading to enhanced profitability

Consolidated net profit was at ₹3,711 crore in Q4 FY25, down from the same period last year.

The EBITDA for the quarter stood at ₹784.6 crore, much higher than the previous level.

Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.

Quarterly revenues of ₹40,674 crore trailed predicted ₹40,747 crore, yet arrived at a 6% sequential year-to-year better than last year's third-quarter ₹38,235 crore

The Board has proposed a final dividend of ₹45 per equity share of face value ₹1 each for the year ended March 31, 2025

The company's balance sheet expanded to ₹65,546 crore as of March 31, 2025, compared to ₹58,171 crore a year earlier.

HUL registered EBITDA of ₹3,466 crore in the March quarter, a 1% year-on-year increase. EBITDA margin for the quarter was 22.8%.

Total revenue, including other revenue, rose to ₹6,066.52 crore in the March quarter, a 12% growth and the highest quarterly revenue in ACC's history.

The company announced a final dividend of ₹10 per equity share for FY25. The record date for the dividend is July 4, 2025.